Healthcare Earnings Report — 2026-06-26 to 2026-08-10

25 most recent Healthcare earnings

1. Aug 10, 2026, 7:35 AM ET·SNDA·Healthcare

   Sonida Senior Living — Second Quarter 2026 Earnings Summary

   SONIDA SENIOR LIVING INC

   Reported a net loss of $24.5 million ($0.52 per share) and Normalized FFO of $23.7 million ($0.48 per share); Adjusted EBITDA rose 30.0% year-over-year to $50.0 million, while Same-Store NOI increased 16.9% to $51.5 million. Completed the acquisition of CNL Healthcare Properties, Inc. on March 11, 2026, integrating its results into the Same-Store Portfolio and expanding the portfolio to 164 communities with $2.55 billion in total assets. Secured a new $380 million Ally Term Loan, drawing $372.5 million to repay existing bridge and term debt and reduce the revolving credit facility, while the ATM program generated $27.3 million in net proceeds from equity sales. Management targets sustained strong NOI growth through organic expansion and disciplined pipeline development, citing an increasingly flexible balance sheet and confidence in delivering long-term shareholder value.

2. Aug 10, 2026, 7:32 AM ET·VREX·Healthcare

   Varex Imaging — Third Quarter Fiscal Year 2026 Earnings Summary

   VAREX IMAGING CORP

   Total revenues reached $210.5 million, a 4% year-over-year increase, driven by strong growth in the Industrial segment and the recovery of previously paid IEEPA tariffs which boosted gross profit by $10 million. Financial results improved significantly versus the prior-year quarter, with GAAP net income turning to $15.7 million ($0.37/share) from a $89.1 million loss, and Non-GAAP net income rising to $13.4 million ($0.31/share) from $5.3 million. The company will not provide Q4 or full-year financial guidance due to the pending transaction with Teledyne Technologies Incorporated, which has also led to the cancellation of the scheduled earnings conference call. Balance sheet updates show long-term debt decreased to $328.9 million while cash and marketable securities declined to $99.2 million; inventories increased to $347.1 million and operating cash flow was $21 million. Future outlook is characterized by "continued momentum" in cargo and vehicle inspection systems, though key risks remain regarding the consummation of the Teledyne transaction, regulatory changes, and supply chain dependencies.

3. Aug 10, 2026, 7:32 AM ET·SGRY·Healthcare

   Surgery Partners, Inc. — Second Quarter 2026 Earnings Summary

   SURGERY PARTNERS INC

   Total revenue rose 2.7% year-over-year to $848.9 million, driven by a 5.0% increase in same-facility revenue, while net loss widened to $15.0 million from $2.5 million in the prior year period. Adjusted EBITDA declined to $125.2 million (14.7% margin) from $129.0 million in the prior year, with operating cash flow falling to $59.3 million from $81.3 million. The Company reaffirmed full-year 2026 revenue guidance of $3.35 billion to $3.45 billion and Adjusted EBITDA guidance of at least $530 million, excluding the pending divestiture of Idaho Falls facilities. Management highlighted the pending sale of Mountain View and Idaho Falls hospitals to Intermountain Health as a key portfolio optimization step to improve financial profile and deleverage, though transaction costs totaled $18.4 million in the quarter.

4. Aug 10, 2026, 7:20 AM ET·SLN·Healthcare

   Silence Therapeutics — Second Quarter 2026 Earnings Summary

   SILENCE THERAPEUTICS PLC

   Cash and cash equivalents increased to $72.1 million as of June 30, 2026, from $11.3 million at December 31, 2025, while net loss narrowed to $12.3 million ($0.09 per share) from $27.4 million ($0.19 per share) in the prior year period. R&D expenses decreased to $9.1 million from $17.6 million year-over-year due to the completion of zerlasiran Phase 3 readiness and reduced personnel costs; G&A expenses also declined to $4.7 million from $5.1 million. Divesiran Phase 2 SANRECO trial dosing is complete for 48 phlebotomy-dependent polycythemia vera patients, while SLN312 Phase 1 results demonstrated favorable safety and durable reductions in atherogenic lipoproteins. Two preclinical programs, SLN365 and SLN098, have shown promising data positioning them for potential IND filings in 2027. Revenue remained at $0 for the quarter, and total shareholders' equity improved to negative $38.5 million from negative $62.3 million at year-end.

5. Aug 10, 2026, 7:19 AM ET·APGE·Healthcare

   Apogee Therapeutics — Second Quarter 2026 Earnings Summary

   APOGEE THERAPEUTICS INC

   Cash, cash equivalents, and marketable securities increased to $1.3 billion as of June 30, 2026, from $621.2 million in the prior year, while total operating expenses rose to $96.0 million from $73.2 million due to higher R&D, G&A, and $4.4 million in merger transaction costs. Net loss widened to $85.9 million for the quarter ended June 30, 2026, compared to $66.1 million in the prior year period, driven by increased operating expenses and $1.6 million in interest expense. The proposed acquisition by AbbVie for $135.11 per share in cash (total equity value ~$10.9 billion) is expected to close in Q3 2026, subject to customary closing conditions. Pipeline progress includes positive Phase 2 results for zumilokibart in atopic dermatitis, with plans to advance to Phase 3 in 2026, initiate ELEVATE Phase 2a for EoE in H2 2026, and initiate ASPIRE Phase 2b for asthma in H1 2027. A $99.2 million revenue share liability was recorded on the balance sheet as of June 30, 2026, contributing to total liabilities rising to $141.2 million from $33.3 million at the end of 2025.

6. Aug 10, 2026, 7:15 AM ET·TNXP·Healthcare

   Tonix Pharmaceuticals — Second Quarter 2026 Earnings Summary

   TONIX PHARMACEUTICALS HOLDING CORP

   Net product revenue surged to $13.5 million in Q2 2026 from $2.0 million in Q2 2025, driven by TONMYA sales of $11.0 million, while net loss widened to $40.6 million ($2.44 per share) from $28.3 million ($3.86 per share) due to increased R&D and SG&A expenses. The company expects current cash resources and anticipated Q3 2026 equity proceeds to fund operations into early Q2 2027, with a managed Medicare agreement covering 9 million lives scheduled to launch January 1, 2027. TONMYA prescriptions grew 100% quarter-over-quarter to 12,592, supported by a sales force expansion to 150 representatives by September 2026 and commercial access to 52 million lives. Pipeline progress includes the initiation of a Phase 2 study for TNX-1500 in the second half of 2026, a planned Phase 2 adaptive field study for TNX-4800 in Q1 2027, and TNX-102 SL enrolling its first patient in the HORIZON study in June 2026. Subsequent to the quarter-end, Tonix raised $3.7 million via its At-the-Market facility, while total cash and equivalents declined to $176.2 million as of June 30, 2026.

7. Aug 10, 2026, 7:15 AM ET·MLTX·Healthcare

   MoonLake Immunotherapeutics — Second Quarter 2026 Earnings Summary

   MOONLAKE IMMUNOTHERAPEUTICS

   Financial Performance: Net loss narrowed to $61.8 million (vs. $69.7 million Q1 2026) with total operating expenses declining to $61.7 million (vs. $70.0 million Q1 2026); cash, equivalents, and short-term marketable debt securities stood at $537.0 million as of June 30, 2026, supporting a runway to mid-2028. Clinical Milestones: The Phase 3 IZAR-1 trial in biologic-naïve PsA patients met all clinical endpoints at Week 16 for the 60 mg dose, demonstrating robust efficacy across ACR, PASI, and functional measures with no new safety signals. Regulatory & Development Outlook: The BLA submission for Hidradenitis Suppurativa (HS) is targeted for late September 2026 with a PDUFA decision expected by November 2026; IZAR-2 enrollment is projected to complete in Q3 2026, while Phase 3 PPP trial enrollment is expected to commence in H2 2026. Capital Structure: Total shareholders' equity increased to $428.2 million (vs. $254.0 million Q1 2026) and the company retains access to up to $400 million in non-dilutive funds through a Hercules Capital debt facility.

8. Aug 10, 2026, 7:13 AM ET·JBIO·Healthcare

   Jade Biosciences — Second Quarter 2026 Earnings Summary

   JADE BIOSCIENCES INC

   Cash, cash equivalents, and investments increased to $461.2 million as of June 30, 2026, from $336.2 million at year-end 2025, extending the cash runway into Q4 2028 following a $172.5 million public offering. Total operating expenses rose to $58.9 million from $27.8 million in the prior year period, driven by higher R&D costs ($50.1 million vs. $22.5 million) and G&A expenses ($8.9 million vs. $5.2 million), resulting in a net loss of $55.8 million compared to $32.1 million previously. JADE101 Phase 2 JUNIPER trial dosing has commenced with positive interim Phase 1 data showing ~70% IgA reductions; a registrational Phase 3 trial is expected to begin in H1 2027 pending FDA feedback. JADE201 Phase 1 dosing for rheumatoid arthritis has begun, while JADE301 is scheduled to initiate a Phase 1 healthy volunteer trial in Q4 2026, with interim data anticipated in H2 2027. The company appointed Mark Eisner, M.D., M.P.H., to the Board of Directors, reinforcing management's conviction to advance the pipeline of best-in-class autoimmune therapies.

9. Aug 10, 2026, 7:05 AM ET·AXSM·Healthcare

   Axsome Therapeutics — Second Quarter 2026 Earnings Summary

   AXSOME THERAPEUTICS INC

   Total net product revenue rose 46% year-over-year to $218.4 million, driven by a 51% increase in AUVELITY sales to $180.3 million and a 461% surge in SYMBRAVO sales to $2.3 million, while net loss widened to $51.3 million ($0.99 per share) from $48.0 million in Q2 2025. SG&A expenses increased 60% to $208.1 million due to commercialization activities for AUVELITY and SYMBRAVO, whereas R&D expenses declined to $46.2 million as costs for AXS-05 and AXS-14 decreased. Management expects commercial momentum to build through year-end, citing strong AUVELITY growth in Alzheimer's disease agitation and major depressive disorder, with cash on hand deemed sufficient to fund operations until cash flow positivity is achieved. Key pipeline milestones include anticipated top-line results for the ENGAGE Phase 3 trial in Q4 2026, the SUSTAIN Phase 3 trial in 2027, and a PDUFA target action date of May 1, 2027, for the AXS-12 NDA submission for cataplexy in narcolepsy. Commercial expansion continues with AUVELITY reaching 89% payer coverage and new-to-brand prescriptions for patients ≥65 increasing 126% in the first eight weeks post-launch, while SYMBRAVO's sales force expansion to 150 representatives is substantially complete.

10. Aug 10, 2026, 7:00 AM ET·ORKA·Healthcare

    Oruka Therapeutics — Second Quarter 2026 Earnings Summary

    ORUKA THERAPEUTICS INC

    Net loss widened to $41.2 million in Q2 2026 from $24.6 million in Q2 2025, driven by a 79% increase in R&D expenses to $43.3 million and higher G&A costs; however, other income net rose to $8.9 million from $3.9 million due to interest earnings. The company secured a $700 million public offering in April 2026, bolstering cash, cash equivalents, and marketable securities to $1.1 billion as of June 30, 2026, which is sufficient to fund operations through the anticipated BLA filing for ORKA-001. Clinical progress includes EVERLAST-B enrollment completion ahead of schedule with Q4 2026 data expectations, ORKA-001 demonstrating 63.5% PASI 100 response in EVERLAST-A, and ORKA-004 expected to enter the clinic in Q4 2026. Strategic updates include an amended IL-23 license agreement with Paragon Therapeutics expanding rights to inflammatory bowel disease and plans to initiate a Phase 3 program for ORKA-001 in the first half of 2027.

11. Aug 10, 2026, 7:00 AM ET·VERU·Healthcare

    Veru Inc. — Fiscal 2026 Third Quarter Earnings Summary

    VERU INC

    Net loss decreased to $7.0 million ($0.30 per share) for the quarter ended June 30, 2026, compared to $7.3 million ($0.50 per share) in the prior year period, while year-to-date net loss narrowed to $15.1 million ($0.68 per share) from $24.2 million ($1.65 per share) in fiscal 2025. Cash position strengthened to $23.9 million as of June 30, 2026, up from $15.8 million at September 30, 2025, driven by $23.3 million in net cash provided by financing activities over the nine-month period. The Phase 2b PLATEAU clinical trial is fully enrolled with 239 patients; interim analysis results are expected in Q1 2027, with final topline data anticipated in Q4 2027. A USPTO notice of allowance was received in August 2026 for a key U.S. patent covering enobosarm and semaglutide regimens, extending protection until at least October 2044. Advancement of the sabizabulin program remains contingent on securing additional funding, and the company plans to prioritize internal cash resources for the PLATEAU trial.

12. Aug 10, 2026, 6:50 AM ET·ACH·Healthcare

    Accendra Health — Second Quarter 2026 Earnings Summary

    ACCENDRA HEALTH INC

    Second quarter 2026 net revenue declined to $613.2 million from $681.9 million in the prior year period, while GAAP and Non-GAAP losses widened compared to the same period in 2025. Full-year 2026 guidance was updated to revenue of $2.45–$2.55 billion, Adjusted EBITDA of $300–$320 million, and free cash flow projected to reach breakeven to slightly positive. The company reduced total debt by $385 million to $1,718.1 million and exited a major commercial payor contract, eliminating over $125 million in annualized operating expenses. CEO Edward A. Pesicka announced his intention to retire by the end of 2026, with the Board initiating a succession process, while the company continues its separation from Owens & Minor. Management expects topline and bottom-line expansion opportunities from new strategic partnerships to emerge in late 2026 and accelerate in 2027.

13. Aug 10, 2026, 6:09 AM ET·AIRS·Healthcare

    AirSculpt Technologies — Second Quarter Fiscal 2026 Earnings Summary

    AIRSCULPT TECHNOLOGIES INC

    Q2 2026 revenue declined 3% to $42.9 million (YTD down 1.3% to $82.3 million), while net loss widened to $1.1 million (YTD $3.5 million) and Adjusted EBITDA fell to $4.9 million (11.5% margin) from $5.8 million (13.3% margin) in the prior year period. The company reduced its full-year 2026 Adjusted EBITDA outlook to $12–$14 million, though it reaffirmed revenue guidance at the lower end of $151–$157 million. Balance sheet improvements include a $30 million debt reduction to $44.2 million and a cash position increase to $18.8 million, driven by an $5.0 million equity raise and $1.4 million debt repayment during the quarter. Strategic updates include an exclusive partnership with AlloClae for a new injectable adipose matrix, while same-center case volume grew 1.0% despite a 2.0% decline in revenue per case. Management noted increased competition from weight-loss drugs and regulatory risks, yet described the company as "fundamentally stronger" with a broader procedure mix and larger addressable market.

14. Aug 10, 2026, 6:07 AM ET·RDNT·Healthcare

    RadNet — Second Quarter 2026 Earnings Summary

    RADNET INC

    Total Company revenue grew 25.0% year-over-year to a record $622.7 million, while Adjusted EBITDA rose 22.7% to $99.7 million; Digital Health revenue surged 56.5% to $32.4 million despite a decline in segment Adjusted EBITDA to $2.5 million due to infrastructure investments. Management revised full-year 2026 Imaging Center guidance upward for Revenue ($2,370–$2,420 million), Adjusted EBITDA ($345–$358 million), and Free Cash Flow ($115–$125 million), while reaffirming Digital Health revenue guidance of $135–$145 million. Strategic growth was driven by a 97.2% year-over-year increase in Digital Health ARR to $105.5 million, a multi-site joint venture with Trinity Health in Boise, and FDA clearance for DeepHealth's breast ultrasound AI solution. Unadjusted Net Income declined to $7.5 million ($0.10 per share) from $14.5 million in the prior year, impacted by $6.6 million in acquisition transaction costs, $3.4 million in debt restructuring losses, and $5.1 million in non-capitalized R&D expenses.

15. Aug 7, 2026, 4:06 PM ET·ENTX·Healthcare

    Entera Bio Ltd. — Second Quarter 2026 Earnings Summary

    ENTERA BIO LTD

    Reported zero revenue for Q2 2026; net loss widened to $7.3 million ($0.14/share) from $2.7 million ($0.06/share) in the prior year period, driven primarily by a $2.7 million non-cash fair value remeasurement of pre-funded warrants. Announced a transformational, oversubscribed $275 million private placement in July 2026 led by BVF Partners, which includes board representation rights and extends the cash runway into 2030 to fund the EB613 Phase 3 program through NDA submission. EB613 Phase 3 registrational study is planned to initiate in late 2026 with topline data expected in H2 2028; an IND application for EB612 is targeted for filing in H1 2027. R&D expenses rose to $3.2 million and G&A expenses increased to $1.4 million for the quarter, reflecting costs associated with the EB613 Phase 3 program and OPKO collaboration activities. Cash and cash equivalents stood at $11.3 million as of June 30, 2026, with an additional $7.1 million in restricted cash designated for the OPKO collaboration.

16. Aug 7, 2026, 4:04 PM ET·ATYR·Healthcare

    aTyr Pharma — Second Quarter 2026 Earnings Summary

    ATYR PHARMA INC

    Consolidated net loss narrowed to $10.3 million for Q2 2026 from $19.5 million in the prior year period, driven by a 46% reduction in total operating expenses to $10.9 million; cash and investments declined to $58.9 million as of June 30, 2026, from $80.9 million at year-end 2025. The company executed a 60% workforce reduction and announced leadership transitions, with CFO Jill Broadfoot and General Counsel Nancy Denyes stepping down in September 2026, while restructuring is projected to reduce annualized operating expenses by approximately $13 million starting in Q4 2026. Cash on hand is expected to fund operations into late 2028, though future development of efzofitimod in its planned Phase 3 pulmonary sarcoidosis study will require additional capital through equity, debt, or partnerships. Key clinical milestones include an anticipated FDA response on the Phase 3 protocol by August 2026 and top-line results from the Phase 2 EFZO-CONNECT study in SSc-ILD expected in Q1 2027.

17. Aug 7, 2026, 8:45 AM ET·ATOS·Healthcare

    Atossa Therapeutics — Second Quarter 2026 Earnings Summary

    ATOSSA THERAPEUTICS INC

    Total operating expenses decreased 3% to $8.7 million in Q2 2026, driven by an 11% drop in R&D costs, though G&A expenses rose 7% to $3.8 million due to patent litigation and compliance fees; net loss widened to $8.5 million ($0.95/share) for the quarter. Cash and cash equivalents declined to $26.1 million as of June 30, 2026, from $41.3 million at year-end, while the company raised $4.5 million in upfront gross proceeds via a registered direct offering with potential total proceeds of $16.5 million. Clinical progress includes the completion of enrollment for the EVANGELINE Phase 2 trial in ER+/HER2- breast cancer and the acceptance of a manuscript supporting (Z)-endoxifen's potential in Duchenne Muscular Dystrophy. The company holds FDA Orphan Drug and Rare Pediatric Disease designations for (Z)-endoxifen in DMD and MAS, with potential eligibility for a Priority Review Voucher valued between $100 million and $220 million. No specific financial guidance was provided; the outlook focuses on advancing the scientific rationale for (Z)-endoxifen in rare pediatric diseases and oncology, supported by new preclinical data on ESR1 mutations.

18. Aug 7, 2026, 8:35 AM ET·XBIO·Healthcare

    Xenetic Biosciences — Second Quarter 2026 Earnings Summary

    XENETIC BIOSCIENCES INC

    Royalty revenue increased 12% to $0.7 million year-over-year, while R&D expenses decreased 16% to $0.6 million; however, G&A expenses rose 64% to $1.1 million due to legal costs related to a strategic review, resulting in a net loss of $0.9 million compared to $0.7 million in the prior-year period. Cash and cash equivalents declined to $6.5 million at quarter-end from $7.9 million at the end of 2025, with $1.5 million in total royalty revenue generated during the first six months of 2026. The Company presented positive preclinical data for DNase I enhancing CAR T-cell outcomes and secured regulatory approval for an investigator-initiated study in large B-cell lymphoma, while advancing its systemic DNase program into clinical trials for pancreatic carcinoma and solid tumors. Management is conducting a strategic review with the Board, citing risks of potential disruption to operations or stock price, while maintaining a disciplined capital allocation approach supported by recurring royalty revenue.

19. Aug 7, 2026, 8:30 AM ET·BIAF·Healthcare

    bioAffinity Technologies — Q2 2026 Earnings Summary

    BIOAFFINITY TECHNOLOGIES INC

    Revenue increased 19% year-over-year to $1.5 million, driven by a 216% surge in CyPath Lung test volume, while the net loss narrowed to $3.4 million from $4.1 million in the prior-year period. Cash reserves declined to $2.4 million as of June 30, 2026, down from $6.4 million at year-end, though a public offering in June 2026 generated approximately $3.2 million in gross proceeds. Strategic priorities for the second half of 2026 focus on expanding physician adoption and introducing CyPath Lung to new healthcare systems, alongside a collaboration with Pictor®, Inc. for next-generation asthma and COPD diagnostics. The company faces significant liquidity and operational risks, including a Nasdaq delisting determination notice, a history of operating losses, and the need to secure adequate financing for commercialization and development activities.

20. Aug 7, 2026, 8:00 AM ET·GYRE·Healthcare

    Gyre Therapeutics — Second Quarter 2026 Earnings Summary

    GYRE THERAPEUTICS INC

    Q2 2026 revenue declined 2% to $29.1 million and YTD revenue fell 11% to $53.5 million; GAAP net loss widened significantly to $14.3 million in Q2 (vs. $2.2 million loss in Q2 2025) and $32.8 million YTD (vs. $2.7 million income YTD 2025), driven by a 129% increase in R&D expenses to $19.1 million. Full year 2026 revenue guidance of $100.5 million to $111.0 million was affirmed, while the company's cash and investments decreased 11% to $103.2 million as of June 30, 2026. Strategic progress includes the May 2026 all-stock acquisition of Cullgen Inc. valued at approximately $300 million, the acceptance of the F351 NDA by China's CDE, and expected IND filings for two Cullgen assets in Q1 2027. Leadership transitioned with Dr. Ying Luo appointed President and CEO, while ETUARYTM sales rose to $28.0 million in Q2 2026, offsetting declines in ContivaTM and EtorelTM sales due to China's centralized procurement program.

21. Aug 7, 2026, 7:13 AM ET·NERV·Healthcare

    Minerva Neurosciences — Second Quarter 2026 Earnings Summary

    MINERVA NEUROSCIENCES INC

    GAAP net income for Q2 2026 was $17.5 million ($0.36/share) versus a $3.3 million loss in the prior year, driven by a $27.6 million non-cash gain on warrant liability; however, GAAP net loss for the six-month period widened to $107.9 million ($2.38/share) from $7.0 million, primarily due to an $81.8 million non-cash loss on warrant liability. Operating expenses increased significantly year-over-year, with R&D rising to $12.4 million for the first half of 2026 from $2.7 million and G&A reaching $14.9 million from $4.6 million, the latter including a $6.6 million one-time non-cash charge for severance and stock option modifications. The company's cash position decreased to $75.4 million as of June 30, 2026, from $82.4 million at year-end 2025, while total liabilities rose to $296.6 million from $233.8 million. Strategic focus remains on the ongoing confirmatory Phase 3 C19 trial for roluperidone, with Phase A topline data expected in H2 2027 and Phase B data in H2 2028; the Scientific Advisory Board was expanded to eleven members to support this late-stage program. Management highlighted a strategic refocus on executing the Phase 3 trial, noting that warrant liability fluctuations stem from the October 2025 private placement and do not reflect operating performance or cash position.

22. Aug 7, 2026, 7:10 AM ET·TMCI·Healthcare

    Treace Medical Concepts — Second Quarter 2026 Earnings Summary

    TREACE MEDICAL CONCEPTS INC

    Reported Q2 2026 revenue of $45.4 million (down 4% YoY) and a net loss of $(15.9) million, though operating expenses decreased 8% YoY to $50.6 million and Adjusted EBITDA improved to $(3.5) million. Raised full-year 2026 revenue guidance to $204–$212 million and narrowed Adjusted EBITDA loss guidance to $3.0–$5.0 million, while reiterating a target for 50% reduction in full-year cash usage. Accelerating case volumes and market share gains are driving adoption of the expanded bunion portfolio, with 40% of Lapiplasty® users now incorporating new systems launched in late 2025. Financial position remains stable with $45.6 million in cash and marketable securities, $56.0 million in long-term debt, and an additional $115 million of liquidity available via the existing credit facility.

23. Aug 7, 2026, 7:07 AM ET·EMBC·Healthcare

    Embecta Corp. — Third Quarter Fiscal 2026 Earnings Summary

    EMBECTA CORP

    Reported Q3 revenue declined 8.1% to $271.7 million (down 24.6% in the U.S. and up 11.5% internationally), while full-year revenue guidance was reaffirmed at $1,015–$1,035 million. Full-year adjusted operating margin guidance was raised to 23.50%–24.00% and adjusted EPS guidance increased to $1.80–$1.90, reflecting improved sequential performance and Owen Mumford integration. Completed the acquisition of Owen Mumford, which contributed $13.8 million to Q3 revenue, and expects GLP-1 small pack format launches in the U.S. in Q4. Returned $62 million to capital structure via $53 million in debt repayments and $9 million in share repurchases, while maintaining a $0.01 quarterly dividend. Net income fell to $21.1 million ($0.36/share) in Q3 from $45.5 million ($0.78/share) prior year, driven by significant U.S. price and volume pressures.

24. Aug 7, 2026, 7:05 AM ET·CGC·Healthcare

    Canopy Growth — Q1 FY2027 Earnings Summary

    CANOPY GROWTH CORP

    Consolidated net revenue rose 13% year-over-year to $81.2M, driven by a 14% increase in the cannabis segment and 6% growth in Storz & Bickel, while consolidated gross margin improved to 27% and adjusted gross margin reached 31%. Net loss narrowed 68% year-over-year to $14.6M, and adjusted EBITDA loss decreased 59% to $3.2M, reflecting disciplined cost management despite a 6% increase in SG&A expenses due to MTL Cannabis integration. Management anticipates further financial improvements in the second half of fiscal 2027 as MTL Cannabis integration completes, expecting synergies from expanded high-quality flower supply and increased revenue opportunities. The company acquired MTL Cannabis, which contributed to growth in medical and adult-use flower segments, while free cash outflow increased to $25.7M primarily due to working capital timing changes.

25. Aug 7, 2026, 7:03 AM ET·KPRX·Healthcare

    Kiora Pharmaceuticals — Second Quarter 2026 Earnings Summary

    KIORA PHARMACEUTICALS INC

    Net loss narrowed to $2.1 million from $2.2 million in Q2 2025, with net loss per share improving to $0.34 from $0.54; cash and short-term investments rose to $16.8 million following a private placement that secured $5.0 million in upfront proceeds. R&D expenses for the quarter were $2.1 million before $1.3 million in reimbursements from Théa, reflecting fully reimbursed costs for the ABACUS-2 trial, while G&A expenses remained flat at $1.4 million. Operational guidance projects funding through late 2028, with ABACUS-2 last patient first visit expected in Q1 2027, topline data in Q3 2027, and initial KLARITY trial data for KIO-104 in late 2026. Management is evaluating strategic transactions to expand the pipeline and satisfy a warrant acceleration milestone, targeting completion by early next year to potentially unlock additional capital from the recent equity financing.